CDT1 and neoplasm: MTD of 50 mg/m2 (schedule A) 50 and 67 mg/m2 (schedule B and C, respectively)11/13 patients with > 20% increase in CDT1 and NRF2 CRLs substrates13/14 patients show NEDD8 adducts in tumor biopsiesClinical activity: 74% SD for schedules B and C